Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces with biotech incubator Flagship Pioneering to drive pre-clinical breakthroughs for cardiometabolic disorders. This collaboration marks the initial phase of a strategic alliance inked in 2022, spotlighting novel therapeutics for cardiometabolic and rare diseases.
As part of this week’s agreement, Novo Nordisk will leverage the epigenomic expertise of Flagship’s Omega Therapeutics (NASDAQ: OMGA) to pioneer an innovative obesity treatment aimed at boosting thermogenesis and metabolic activity. Additionally, Novo will work alongside Flagship’s Cellarity to identify novel biological mechanisms and develop a small-molecule therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Under the terms of the deal, Novo Nordisk will shoulder research and development costs, offering both Omega and Cellarity up to USD 532 million in upfront and milestone-based payments, along with future royalties tied to sales.- Flcube.com
